Close Menu

NEW YORK – Although there are well-established treatments for many of the cancers that occur in children, there are cases where reliable treatments do not exist, particularly for pediatric cancers that recur.

Those difficult-to-treat cases are among those being tackled through KidsCanSeq, a Texas-based  genomics-centered pediatric oncology study. The effort was launched in 2018 with $2.8 million in funding from the second phase of the National Human Genome Research Institute's Clinical Sequencing Evidence-Generating Research Consortium, known as CSER2.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

Nov
17

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.

Nov
23
Sponsored by
Inivata

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment.